Labo Euromedis (STU:61R) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:61R Labo Euromedis STU:61R
66 GF Score
Price €5.00
GF Value €4.33
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Labo Euromedis Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Labo Euromedis  (STU:61R) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Labo Euromedis Cyclically Adjusted PS Ratio Related Terms


Labo Euromedis Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Labo Euromedis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labo Euromedis Cyclically Adjusted PS Ratio Chart

Labo Euromedis Annual Data
Trend Jul15 Jul16 Jul17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Labo Euromedis Semi-Annual Data
Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.13 0.15 0.15 0.14

STU:61R vs MCK, COR, CAH: Cyclically Adjusted PS Ratio Comparison

For the Medical Distribution subindustry, Labo Euromedis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labo Euromedis Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Labo Euromedis's Cyclically Adjusted PS Ratio falls into.


STU:61R
66GF Score
Labo Euromedis STU:61R
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labo Euromedis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Labo Euromedis's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Labo Euromedis's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=14.306/120.8900*120.8900
=14.306

Current CPI (Dec25) = 120.8900.

Labo Euromedis Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201507 24.046 100.030 29.060
201607 24.658 100.250 29.735
201707 24.752 100.970 29.635
201912 25.772 104.980 29.678
202012 54.437 104.960 62.699
202112 31.408 107.850 35.205
202212 18.533 114.160 19.626
202312 11.948 118.390 12.200
202412 12.733 119.950 12.833
202512 14.306 120.890 14.306

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Labo Euromedis (STU:61R) Overvalued in 2026?

Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued. The current stock price of €5.00 is trading 15.5% above its estimated GF Value™ of €4.33. GuruFocus considers Labo Euromedis to be Modestly Overvalued.

Key valuation signals for STU:61R:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €4.33 vs. price of €5.00 (15.5% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the STU:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Labo Euromedis Business Description

Other Exchanges 0I0L:UKALEMG:France
Address ZI de la Tuilerie, Neuilly-sous-Clermont, FRA, 60290
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
66GF Score

Get the complete analysis for STU:61R

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.00
Price
€4.33
GF Value